Use of anticytokine therapies, such as tocilizumab (anti-IL-6) has been suggested by some studies as a promising treatment, which may be capable of reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 [17–19]. This evidence concerns the gene IL6 and COVID-19.